• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >A new class of biologic agents facing the therapeutic paradigm in psoriasis: Anti-IL-23 agents
【24h】

A new class of biologic agents facing the therapeutic paradigm in psoriasis: Anti-IL-23 agents

机译：一类面临牛皮癣治疗范式的新一类生物蛋白：抗IL-23代理商

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Psoriasis is a chronic inflammatory skin disease whose pathogenesis is driven by multiple cytokine-mediated pathways. In this immunologic setting, the centrality of the IL-23/IL-17 axis and its therapeutic relevance has emerged. Areas covered: This review is aimed at collecting preliminary data on IL23p19 blockers developed for the treatment of plaque psoriasis. Three agents, guselkumab, risankizumab, and tildrakizumab, are currently being tested in phase III trials, while LY2525623 is currently being tested in phase II trials. Treatment with these agents resulted in a marked improvement in disease severity, confirming the pathogenic relevance of IL-23 in psoriasis. Expert opinion: Selective neutralization of IL-23 is an advantageous strategy for treating psoriasis. Preliminary data from phase II and III trials have shown the capability of this therapeutic class in inducing complete clearance or almost complete clearance in many patients: the highest PASI 90 rates were achieved by guselkumab, tildrakizumab, and risankizumab in 73.3%, 74% and 77% of cases, respectively. Moreover, the highest PASI 100 rates were achieved in 33%, 14%, and 48% of patients treated with guselkumab, tildrakizumab, and risankizumab, respectively. Further studies are needed to confirm this remarkable efficacy over long-term treatment periods.
机译：介绍：牛皮癣是一种慢性炎症皮肤病，其发病机制由多种细胞因子介导的途径驱动。在这种免疫环境中，出现了IL-23 / IL-17轴的中心性及其治疗相关性。所涵盖的地区：本综述旨在收集对IL23P19封锁器的初步数据，为治疗斑块牛皮癣。目前在第三阶段试验中测试了三种代理人，Guselkumab，Risankizumab和TiNDrokizumab，而Ly2525623目前正在第二阶段试验中进行测试。用这些药剂治疗导致疾病严重程度的显着改善，确认IL-23在牛皮癣中的致病相关性。专家意见：IL-23的选择性中和是治疗牛皮癣的有利策略。 II期和III阶段试验的初步数据表明了这种治疗阶级在许多患者中诱导完全清除或几乎完全清除的能力：Guselkumab，Tiantrokizumab和Risankizumab的最高PASI 90率为73.3％，74％和77分别占病例的％。此外，最高的PASI 100率为33％，14％和48％的患者分别达到了Guselkumab，Tiandrakizumab和Risankizumab的患者。需要进一步的研究来确认在长期治疗期间的这种显着效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号